Now, a new concern has emerged stomach paralysis
Not Drinking Enough Water When appetite decreases, fluid intake often drops as well
Conclusion: Among (MASLD) patients, resmetirom might significantly reduce hepatic fat, inflammation, liver enzymes, lipoprotein (a), and atherogenic lipids, which are markers of inflammation and fibrosis in MASLD patients, in addition, we need more studies to see the difference more clearly
This represents a shared decision-making opportunity between patient and providers
Understanding the Current GLP-1 Landscape and Why Alternatives Are Being Sought The weight management medication market has changed dramatically since semaglutide-based treatments gained wide attention
In patients with type 2 diabetes, however, this balance breaks down